Stimulants pp 243-333 | Cite as

Psychotomimetic Drugs: Structure-Activity Relationships

  • Alexander T. Shulgin
Part of the Handbook of Psychopharmacology book series (HBKPS, volume 11)


The field of psychopharmacology has its sources in a number of different medical disciplines involved with the function of the brain. In the area of pharmacology, a major contribution has been made by the study of those drugs that are collectively known as psychotropic agents. The term “psychotropic” is used to describe a drug that turns or changes the mind, following quite literally from the Greek stemψυχη meaning soul, mind, or understanding, and τρεπειν, to turn. A sizable proportion of our present pharmacopoea contains medicines designed to play a role in the changing or modification of a person’s mood or mental state. A classification of these materials into families defined by the nature of the mental state change evoked is a useful way of defining the subdivision known as “psychotomimetic drugs.” An historically interesting procedure was established by Lewin (1924), who characterized these drugs in five subdivisions according to the nature of their action.


Positional Isomer Methoxyl Group Hydrochloride Salt Lysergic Acid Lysergic Acid Diethylamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abood, L. G., 1968, The psychotomimetic glycolate esters, in Drugs Affecting the Central Nervous System (A. Burger, ed.), pp. 127–167, Marcel Decker, New York.Google Scholar
  2. Abramson, H. A., 1959, Lysergic acide diethylamide (LSD-25): XXIX. The response index as a measure of threshold activity of psychotropic drugs in man, J. Psych. 48:65–78.CrossRefGoogle Scholar
  3. Abramson, H. A., and Rolo, A., 1967, Comparison of LSD with methysergide and psilocybin on test subjects, in The Use of LSD in Psychotherapy and Alcoholism (H. A. Abramson, ed.), pp. 53–73, Bobbs Merrill, New York.Google Scholar
  4. Agurell, S., 1969a, Cactaceae alkaloids. I. Lloydia 32:206–216.PubMedGoogle Scholar
  5. Agurell, S., 1969b, Identification of alkaloid intermediates by gas chromatography-mass spectrometry. I. Potential mescaline precursors in Trichocereus species, Lloydia 32:40–45.PubMedGoogle Scholar
  6. Agurell, S., Bruhn, J. G., Lundstrom, J., and Svensson, U., 1971, Cactaceae alkaloids. X. Alkaloids of Trichocereus species and some other cactii, Lloydia 34:183–187.Google Scholar
  7. Aldous, F. A. B., Barrass, B. C., Brewster, K., Buxton, D. A., Green, D. M., Pinder, R. M., Rich, P., Skeels, M., and Tutt, H. J., 1974, Structure-activity relationships in psychotomimetic phenylalkylamines, J. Med. Chem. 17:1100–1111.PubMedCrossRefGoogle Scholar
  8. Alles, G. A., 1933, The comparative physiological actions of dl-β-phenylisopropylamines. I. Pressor effects and toxicity. J. Pharm. Exp. Ther. 47:339–354.Google Scholar
  9. Alles, G. A., 1959, Some relations between chemical structure and physiological action of mescaline and related compounds, in Neuropharmacology, Trans. Fourth Conf. (H. A. Abramson, ed.), pp. 181-268, J. Macy, Jr. Foundation.Google Scholar
  10. Anderson, G., III, Kollman, P., Jacob, P., III, Shulgin, A. T., and Castagnoli, N., Jr., 1977, The synthesis and pharmacological evaluation of ring substituted 1-phenyl-2-aminopropanes, paper presented at ACS 173rd Natl. Meeting, New Orleans, March 21–25.Google Scholar
  11. Andreoli, V. M., Danieli, B., and Tonon, G. C., 1973, Significance of methoxylated derivatives in amphetamine psychosis, Riv. Farmacol. Ter. 4(4):1a–21a (CA:81:20757c).Google Scholar
  12. Angrist, B. M., and Gershon, S., 1970, The phenomenology of experimentally induced amphetamine psychosis—preliminary observations, Biol. Psychiat. 2:95–107.PubMedGoogle Scholar
  13. Angrist, B. M., Schweitzer, J. W., Gershon, S., and Friedhoff, A. J., 1970a, Mephentermine psychosis: Misuse of the wyamine inhealer, Am. J. Psychiat. 126:1315–1317.PubMedGoogle Scholar
  14. Angrist, B. M., Schweitzer, J. W., Friedhoff, A. J., and Gershon, S., 1970b, Investigation of p-methoxyamphetamine excretion in amphetamine induced psychosis, Nature 225:651–662.PubMedCrossRefGoogle Scholar
  15. Angrist, A., Rotrosen, J., and Gershon, S., 1974, Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacologia 36:203–207.PubMedCrossRefGoogle Scholar
  16. Anonymous, 1959, Therapeutic compositions containing 1-(2,4-dimethylphenyl)-2-aminopropane, Br. Patent 819,129 (CA: 54:10245).Google Scholar
  17. Anonymous, 1970, Listing of MDA (methylenedioxyamphetamine), MMDA (methoxymethylenedioxyamphetamine), TMA (trimethoxyamphetamine), JB-318 (N-ethyl-3(2)(4)-piperidylbenzilate), and JB-336 (N-methyl-3(2)(4)-piperidylbenzilate) and their salts as subject to control, Fed. Reg. 35:7069-7070.Google Scholar
  18. Anonymous, 1973a, Physician’s Desk Reference, p. 1319, Medical Economics Company, Oradell, New Jersey.Google Scholar
  19. Anonymous, 1973b, para-Methoxyamphetamine (PMA), Microgram 6:66-71.Google Scholar
  20. Anonymous, 1976, Proposed revised aggregate production quota for 1976; 2,5-dimethoxyamphetamine. Fed. Reg. 41:21208.Google Scholar
  21. Antun, F., Smythies, J. R., Benington, F., Morin, R. D., Barfknecht, C. F., and Nichols, D. E., 1971, Native fluorescence and hallucinogenic potency of some amphetamines, Experientia 27:62–63.PubMedCrossRefGoogle Scholar
  22. Bailey, K., 1972, The mass spectra of dimethoxyamphetamine hydrochlorides, Anal. Chim. Acta 60:287–292.PubMedCrossRefGoogle Scholar
  23. Bailey, K., Beckstead, H. D., Legault, D., and Verner, D., 1974a, Identification of 2-, 3-, and 4-methoxyamphetamines and 2-, 3-, and 4-methylamphetamines, J.A.O.A.C. 57:1134–1143.Google Scholar
  24. Bailey, K., Legault, D., and Verner, D., 1974b, Spectroscopic identification of dimethoxyamphetamines, J.A.O.A.C. 57:70–78.Google Scholar
  25. Bailey, K., By, A. W., Legault, D., and Verner, D., 1975, Identification of the N-methylated analogs of the hallucinogenic amphetamines and some isomers, J.A.O.A.C. 58:62–69.Google Scholar
  26. Bailey, K., Gagné, D. R., and Pike, R. K., 1976, Investigation and identification of the bromination products of dimethoxyamphetamines, J.A.O.A.C. 59:1162–1169.Google Scholar
  27. Baker, R. W., Chothia, C., Pauling, P., and Weber, H. P., 1973, Molecular structures of hallucinogenic substances: Lysergic acid diethylamide, psilocybin and 2,4,5-trimethoxyamphetamine, Mol. Pharmacol. 9:23–32.PubMedGoogle Scholar
  28. Barfknecht, C. F., and Nichols, D. E., 1971, Potential psychotomimetics. Bromomethoxyamphetamines, J. Med. Chem. 14:370–372.PubMedCrossRefGoogle Scholar
  29. Barfknecht, C. F., Nichols, D. E., and Dunn, W. J., 1975, Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients, J. Med. Chem. 18:208–210.PubMedCrossRefGoogle Scholar
  30. Beaton, J. M., Smythies, J. R., Benington, F., Morin, R. D., and Clark, L. C., 1968, Behavioral effects of some 4-substituted amphetamines Nature 220:800–801.PubMedCrossRefGoogle Scholar
  31. Bell, D. S., 1965, Comparison of amphetamine psychosis and schizophrenia, Br. J. Psychiatry 111:701–717.PubMedCrossRefGoogle Scholar
  32. Benington, F., Morin, R. D., and Clark, L. C., 1954, Mescaline analogs, I. 2,4,6-Trimethoxy-β-phenethylamines, J. Org. Chem. 19:11–16.CrossRefGoogle Scholar
  33. Benington, F., Morin, R. D., Clark, L. C., and Fox, R. P., 1958, Psychopharmacological activity of ring-and side chain-substituted beta-phenethylamines, J. Org. Chem. 23:1979–1984.CrossRefGoogle Scholar
  34. Benington, F., Morin, R. D., Beaton, J., Smythies, J. R., and Bradley, R. J., 1973, Comparative effects of stereoisomers of hallucinogenic amphetamines, Nature 242:185–186.Google Scholar
  35. Beringer, K., 1927, Der meskalinrauche. Seine Geschichte und Erscheinungsweise, Verlag Julius Springer, Berlin.Google Scholar
  36. Biniecki, S., and Krajewski, E., 1960, Preparation of DL-1-(3,4-methylenedioxyphenyl)-2-(methylamine)propane and DL-1-(3,4-dimethoxyphenyl)-2-(methylamino)-propane, Acta Polon. Pharm. 17:421.Google Scholar
  37. Biniecki, S., and Muszynski, E., 1953, Synthesis of amphetamine derivatives, Acta Polon. Pharm. 10:211–221.Google Scholar
  38. Bosin, T. R., Campaigne, E., Dinner, A., Rogers, R. B., and Maickel, R. P., 1976, Comparative toxicological studies of indole, benzo(b)thiophene, and 1-methylindole derivatives, J. Toxico. Environ. Health 1:515–520.CrossRefGoogle Scholar
  39. Braun, G., and Shulgin, A. T., 1976, Unpublished data.Google Scholar
  40. Braun, J. G., 1975, Pharmacognostic Studies of Peyote and Related Psychoadive Cadi, Doctoral thesis, Uppsala University.Google Scholar
  41. Braun, U., and Kalbhen, D. A., 1972, Nachweis der Bildung psychotroper Amphetamin-Derivate aus Inhaltsstoffen der Muskatness, Deut. Med. Woch. 97:1614.CrossRefGoogle Scholar
  42. Braun, U., and Kalbhen, D. A., 1973, Evidence for the biogenic formation of amphetamine derivatives from components of nutmeg, Pharmacology 9:312–316.PubMedCrossRefGoogle Scholar
  43. Braun, U., Shulgin, A. T., Braun, G., and Sargent, T., III, 1977, Brain visualization agents: The synthesis and body distribution of several 131I-labelled CNS-active drugs, J. Med. Chem. in press.Google Scholar
  44. Bravo, H. H., 1967, Una revisión del género Lophophora, Cad. Sucul. Mex. 12:8.Google Scholar
  45. Brawley, P., and Duffield, J. C., 1972, The pharmacology of hallucinogens, Pharm. Rev. 24:31–66.PubMedGoogle Scholar
  46. Brimblecombe, R. W., 1963, Effects of psychotropic drugs on the open field behavior in rats, Psychopharmacologia 4:139–147.PubMedCrossRefGoogle Scholar
  47. Brimblecombe, R. W., 1967, Hyperthermic effects of some tryptamine derivatives in relation to their behavioral activity, Int. J. Neuropharm. 6:423–429.CrossRefGoogle Scholar
  48. Brimblecombe, R. W., and Pinder, R. M., 1975, Hallucinogenic Agents, Scientechnica, Bristol.Google Scholar
  49. Brimblecombe, R. W., Downing, D. F., Green, D. M., and Hunt, R. R., 1964, Some pharmacological effects of a series of tryptamine derivatives, Br. J. Pharmacol. 23:43–54.Google Scholar
  50. Brown, H. D., 1958, Antitussive compositions, U.S. Patent 2,820,739 (Jan. 21, 1958).Google Scholar
  51. Brown, W. T., McGeer, P. L., and Moser, I., 1968, Lack of psychotomimetic effect of paramethoxyphenylethylamine and 3,4-dimethoxyphenethylamine in man, Can. Psychiat. J. 13:91–92.Google Scholar
  52. Bruckner, V., 1933, Über das Pseudonitrosit des Asarons, J. Prakt. Chem. 138:268–274.CrossRefGoogle Scholar
  53. Bueno, O. F. A., 1975, Mescaline and homoveratrylamine as discriminative stimuli in rats, Acta Physiol. Lat. Am. 25:77–79.PubMedGoogle Scholar
  54. Burger, A., and Foggio, R. D., 1956, Nuclear substituted 3,4-dihydroxyphenethylamines and related derivatives, J.A.C.S. 78:4419–4422.CrossRefGoogle Scholar
  55. Buu-Hoi, N. P., and Petit, L., 1960, Some homologs of α,α-dimethyl-β-phenethylamine, J. Org. Chem. 25:726–728.CrossRefGoogle Scholar
  56. Campaigne, E., and Knapp, D. R., 1970, Benzo(b)thiophene derivatives. XIV. Derivatives of naphtho(1,8-c)thiophene, J. Heterocycl. Chem. 7:107.CrossRefGoogle Scholar
  57. Carlini, E. A., Silva, M. T. A., Cesare, L. C., and Endo, R. M., 1967, Effects of chronic administration of beta-(3,4-dimethoxyphenyl)-ethylamine and beta-(3,4,5-trimethoxyphenyl)-ethylamine on the climbing rope performance of rats, Med. Pharmacol. Exp. 17:534–542.Google Scholar
  58. Carlsson, A., Corrodi, H., and Magnusson, T., 1963, Basische Derivate des 4,5,6-Trimethoxyindols und des 3,4,5-Trimethoxyphenols, Helv. Chim. Acta 46:1231–1235.CrossRefGoogle Scholar
  59. Carlsson, A., Lindquist, M., Wysokowski, J., Corrodi, H., and Junggren, U., 1970, Substituted meta-tyramines as brain monoamine depletors, Acta Pharm. Suecica 7:293–302.Google Scholar
  60. Cerletti, A., 1959, in Neuro-Psychopharmacology (P. B. Bradley, P. Deniker, and C. Radouco-Thomas, eds.), Elsevier, Amsterdam.Google Scholar
  61. Charalampous, K. D., and Tansey, L. W., 1967, Metabolic fate of β-(3,4-dimethoxyphenyl)-ethylamine in man, J. Pharm. Exp. Ther. 155:318–329.Google Scholar
  62. Charalampous, K. D., Orengo, A., Walker, K. E., and Kinross-Wright, J., 1964, Metabolic fate of β-(3,4,5-trimethoxyphenyl)-ethylamine (mescaline) in humans: Isolation and identification of 3,4,5-trimethoxyphenylacetic acid, J. Pharm. Exp. Ther. 145:242–246.Google Scholar
  63. Charalampous, K. D., Walker, K. E., and Kinross-Wright, J., 1966, Metabolic fate of mescaline in man, Psychopharmacologia 9:48–63.PubMedCrossRefGoogle Scholar
  64. Cheng, H. C., Long, J. P., Nichols, D. E., and Barfknecht, C. F., 1974, Effects of paramethoxyamphetamine (PMA) on the cardiovascular system of the dog, Arch. Int. Pharmacol. Ther. 212:83–88.Google Scholar
  65. Chothia, C., and Pauling, P., 1969, On the conformations of hallucinogenic molecules and their correlations, Proc. Natl. Acad. Sci. 63:1063–1070.PubMedCrossRefGoogle Scholar
  66. Cimbura, G., 1974, PMA deaths in Ontario, J. Can. Med. Assoc. 110:1263–1267.Google Scholar
  67. Clark, L. C., Benington, F., and Morin, R. D., 1965, The effects of ring-methoxy groups on biological deamination of phenethylamines, J. Med. Chem. 8:353–355.PubMedCrossRefGoogle Scholar
  68. Cohen, I., Fischer, J. F., and Vogel, W. H., 1974, Physiological disposition of beta-phenethylamine, 2,4,5-trimethoxyphenethylamine, 2,3,4,5,6-pentamethoxyphenethylamine, and beta-hydroxymescaline in rat brain, liver, and plasma, Psychopharmacologia 36:77–84.PubMedCrossRefGoogle Scholar
  69. Cohen, S., 1960, Lysergic acid diethylamide: Side effects and complications. J. Nerv. Mental. Dis. 130:30–40.CrossRefGoogle Scholar
  70. Connell, P. H., 1958, Amphetamine Psychosis, Maudsley Monographs No. 5, Chapman and Hall, London.Google Scholar
  71. Cook, L., and Fellows, E. J., 1961, Anorexigenic preparation and method of curbing the appetite, U.S. Patent 2,974,148 (March 7, 1961).Google Scholar
  72. Cordova, V., 1974, Analytical data on 4-methyl amphetamine sulfate, Microgram 7:196–208.Google Scholar
  73. Corne, S. J., and Pickering, R. W., 1967, A possible correlation between drug-induced hallucinations in man and a behavioral response in mice, Psychopharmacologia 11:65–78.PubMedCrossRefGoogle Scholar
  74. Coutts, R. T., and Malicky, J. L., 1973, The synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), Can. J. Chem. 51:1402–1409.CrossRefGoogle Scholar
  75. Dallacker, F., 1969, Derivatives of methylenedioxybenzene. XXVIII. Reactions of the dimethoxymethylenedioxybenzaldehydes, Monat Chem. 100:742–747.CrossRefGoogle Scholar
  76. Davis, V. E., and Walsh, M. J., 1970, Alcohol, amines, and alkaloids: A possible biochemical basis for alcohol addiction, Science 167:1005–1007.PubMedCrossRefGoogle Scholar
  77. Delay, J., 1959, Classification of psychotropic drugs, in Psychopharmacology Frontiers (N. S. Klein, ed.), Churchill, London.Google Scholar
  78. Deniker, P., Peron-Magnan, P., Guillou, C. E. L., and Hanus, M., 1971, Essais cliniques d’une amphétamine antidépressive originale, la d-l-para-chloro-N-methylamphétamine ou Ro 4 6861, Therapie 26:219–226.PubMedGoogle Scholar
  79. De Vries, J. X., Moyna, P., Dias, V., Agurell, S., and Bruhn, J. G., 1971, Alcaloides de cactos del Uruguay, Rev. Latinoam. Quim. 2:21–23.Google Scholar
  80. De Zan, P., 1971, Analysis and identification of 2,5-dimethoxyamphetamine, Microgram 4:5–11.Google Scholar
  81. De Zorsi, C., and Cavalli, A., 1974, Un nuovo allucinogeno: La MMA (P-metil-M-metossi anfetamina), Zacchia 10:3–11.Google Scholar
  82. Dittrich, A., 1971, Alteration of behavioral changes induced by 3,4,5-trimethoxyphenylethylamine (mescaline) by pretreatment with 2,4,5-trimethoxyphenylethylamine. A self-experiment, Psychopharmacologia 21:229–237.PubMedCrossRefGoogle Scholar
  83. Dixon, W. E., 1899, The physiological action of the alkaloids derived from Anhalonium lewinii, J. Physiol. 25:69–86.PubMedGoogle Scholar
  84. Dyer, D. C., Nichols, D. E., Rusterholz, D. B., and Barfknecht, C. F., 1973, Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines, Life Sci. 13:885–896.PubMedCrossRefGoogle Scholar
  85. Elkes, C., Elkes, J., and Mayer-Gross, W., 1955, Hallucinogenic drugs, Lancet 268:719.CrossRefGoogle Scholar
  86. Ellis, H., 1898, Mescal, a new artificial paradise, Ann. Rep. Smithsonian Inst. 1897:537–548, U.S. Govt. Printing Office.Google Scholar
  87. Epstein, D., Gunn, J. A., and Virden, C. J., 1932, The action of some amines related to adrenalin. I. Methoxyphenethylamines, J. Physiol. 76:224–246.PubMedGoogle Scholar
  88. Ernst, A. M., 1962, Phenomena of the hypokinetic rigid type caused by O-methylation of dopamine in the para-position, Nature 193:178–179.PubMedCrossRefGoogle Scholar
  89. Ernst, A. M., 1965, Relation between the structure of certain methoxyphenylethylamine derivatives and the occurrence of a hypokinetic rigid syndrome, Psychopharmacologia 7:383–390.PubMedCrossRefGoogle Scholar
  90. Faillace, L. A., Snyder, S. H., and Weingartner, H., 1970, 2,5-Dimethoxy-4-methylamphetamine: Clinical evaluation of a new hallucinogenic drug, J. Nerv. Mental. Dis. 150:119–126.CrossRefGoogle Scholar
  91. Fairchild, M. D., 1963, Some Central Nervous System Effects of Four Phenylsubstituted Amphetamine Derivatives, Ph.D. thesis, U.C.L.A.Google Scholar
  92. Fairchild, M. D., Alles, G. A., Jenden, D. J., and Mickey, M. R., 1967, The effects of mescaline, amphetamine, and four ring-substituted amphetamine derivatives on spontaneous brain electrical activity in the cat, Int. J. Neuropharm. 6:151–167.CrossRefGoogle Scholar
  93. Forrest, J. E., and Heacock, R. A., 1972, Nutmeg and mace, the psychotropic spices from Myristica fragrans, Lloydia 35:440–449.PubMedGoogle Scholar
  94. Friedhoff, A. J., and Hollister, L. E., 1966, Comparison of the metabolism of 3,4-dimethoxyphenylethylamine and mescaline in humans, Biochem. Pharmacol. 15:269–273.PubMedCrossRefGoogle Scholar
  95. Friedhoff, A. J., and Schweitzer, J. W., 1968, An effect of N-acetyldimethoxyphenethylamine, Dis. Nerv. System 29:455–456.Google Scholar
  96. Friedhoff, A. J., and Van Winkle, E., 1962, Isolation and characterization of a compound from the urine of schizophrenics, Nature 194:867–868.CrossRefGoogle Scholar
  97. Fuller, R. W., Hines, C. W., and Mills, J., 1965, Lowering of brain serotonin levels by chloramphetamines, Biochem. Pharmacol. 14:483–488.PubMedCrossRefGoogle Scholar
  98. Fuller, R. W., Baker, J. C., Perry, K. W., and Molloy, B. B., 1975, Comparison of 4-chloro-, 4-bromo-and 4-fluoroamphetamin in rats. Drug levels in brain and effects on brain serotonin metabolism, Neuropharmacology 14:739–746.PubMedCrossRefGoogle Scholar
  99. Furst, P. T. (ed.), 1972, Flesh of the Gods, the Ritual Use of the Hallucinogens, Praeger, New York.Google Scholar
  100. Gaston, T. R., and Rasmussen, G. T., 1972, Identification of 3,4-methylenedioxymethamphetamine, Microgram 5:60.Google Scholar
  101. Greenberg, J. R., and Lustig, N., 1966, Misuse of Dristan inhaler, N.Y.J. Med. 66:613–617.Google Scholar
  102. Griffith, J. D., Cavanaugh, J. H., Held, J., and Oates, J. A., 1970, Experimental psychosis induced by the administration of d-amphetamine, in Amphetamines and Related Compounds (E. Costa and S. Garrattini, eds.), pp. 897–904, Raven Press, New York.Google Scholar
  103. Guenther, E., 1952, Oil of calamus, in The Essential Oils, Vol. VI, pp. 109–117, Van Nostrand, New York.Google Scholar
  104. Gunn, J. A., Gurd, M. R., and Sachs, I., 1939, The action of some amines related to adrenaline: Methoxyphenylisopropylamines, J. Physiol. 95:485–500.PubMedGoogle Scholar
  105. Haase, H. J., 1966, Neuroleptika, Tranquilizer und Antidepressiva in Klinik und Praxis, Janssen, Dusseldorf.Google Scholar
  106. Hall, C. S., 1934, Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality, J. Comp. Psych. 18:385–403.CrossRefGoogle Scholar
  107. Hambourger, W. E., and Jamieson, R. B., Jr., 1936, Comparison of the pressor effects of some new alkyl derivatives of β-phenylethylamines, J. Pharm. Exp. Ther. 58:53–61.Google Scholar
  108. Hardman, H. F., Haavik, C. O., and Seevers, M. H., 1973, Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals, Toxicol. Appl. Pharm. 25:299–309.CrossRefGoogle Scholar
  109. Harris, S. C., and Worley, R. C., 1957, Analgesic properties of xylopropamine, Proc. Soc. Exp. Biol. Med. 95:212–215.PubMedGoogle Scholar
  110. Harrison, S. D., Bosin, T. R., and Maickel, R. P., 1974, Metabolism of the benzo(b)thiophene analog of N,N-dimethyltryptamine in vivo and in vitro in the rat. Application of organic chemical and spectroscopic techniques to problems of drug metabolism, Drug Metabol. Disp. 2:228–236.Google Scholar
  111. Harvey, J. A., and McMaster, S. E., 1976, Neurotoxic action of para-chloroamphetamine in the rat as revealed by Nissl and silver stains, Psychopharmacol. Bull. 12(3):62–64.PubMedGoogle Scholar
  112. Heffter, A., 1898, Ueber pellote, Arch. Exp. Path. Pharmakol. 40:385–429.CrossRefGoogle Scholar
  113. Hellpach, W., 1941, Funktionelle Differenzierung der “psychischen Stimulantein,” Deut. Med. Wochen. 67:1358.CrossRefGoogle Scholar
  114. Hernñndez, F., 1651, Nova Plantarum, Animalium et Mineralium Mexicanorum Historia, B. Deuersini and Z. Masotti, Rome.Google Scholar
  115. Hey, P., 1947, The synthesis of a new homolog of mescaline, Quart. J. Pharm. Pharmacol. 20:129–134.Google Scholar
  116. Ho, B. T., 1975, Metabolism of hallucinogens in brain and other tissues, Psychopharmacol. Bull. 11:61–62.PubMedGoogle Scholar
  117. Ho, B. T., Tansey, L. W., Balster, R. L., An, R., McIsaac, W. M., and Harris, R. T., 1970a, Amphetamine analogs. II. Methylated phenylethylamines, J. Med. Chem. 13:134–135.PubMedCrossRefGoogle Scholar
  118. Ho, B. T., McIsaac, W. M., An, R., Tansey, L. W., Walker, K. E., Englert, L. F., Jr., and Noel, M. B., 1970b, Analogs of alpha-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs, J. Med. Chem. 13:26–30.PubMedCrossRefGoogle Scholar
  119. Ho, B. T., Estevez, V., and Fritschie, G. E., 1971a, The fate of 2,5-dimethoxy-4-methylamphetamine (STP, DOM) in monkey and rat brains, Brain Res. 29:166–169.PubMedCrossRefGoogle Scholar
  120. Ho, B. T., Estevez, V., Tansey, L. W., Englert, L. F., Creaven, P. J., and McIsaac, W. M., 1971b, Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats, J. Med. Chem. 14:158–160.PubMedCrossRefGoogle Scholar
  121. Hoch, P. H., 1951, Experimentally produced psychoses, Am. J. Psychiat. 107:607–611.PubMedGoogle Scholar
  122. Hoffer, A., and Osmond, H., 1967, The Hallucinogens, pp. 55–56. Academic Press, New York.Google Scholar
  123. Hofmann, A., 1959, Psychotomimetic drugs: Chemical and pharmacological aspects, Acta Physiol. Pharmacol. Neerl. 8:240–258.PubMedGoogle Scholar
  124. Hofmann, A., 1960, Psychotomimetics: Chemical, pharmacological and medical aspects, Svensk. Kern. Tidskr. 72:723–747.Google Scholar
  125. Hofmann, A., 1968, Psychotomimetic agents, in Drugs Affecting the Nervous System, Vol. 2 (A. Burger, ed.), pp. 169–235, Marcel Dekker, New York.Google Scholar
  126. Hollister, L. E., and Friedhoff, A. J., 1966, Effects of 3,4-dimethoxyphenylethylamine in man, Nature 210:1377–1378.PubMedCrossRefGoogle Scholar
  127. Hollister, L. E., Macnicol, M. F., and Gillespie, H. K., 1969, An hallucinogenic amphetamine analog (DOM) in man, Psychopharmacologia 14:62–73.PubMedCrossRefGoogle Scholar
  128. Horii, A., and Inoi, T., 1957, Syntheses of arylalkylamines. IV. Syntheses of α-methyl-2-alkoxyphenethylamines and nuclear substituted derivatives. Yakugaku Zasshi 77:1095–1100 (CA 52:5318i).Google Scholar
  129. Horita, A., and Dille, J. M., 1954, The pyretogenic effect of lysergic acid diethylamide, Science 120:1100–1101.PubMedCrossRefGoogle Scholar
  130. Hunt, R. R., and Brimblecombe, R. W., 1967, Synthesis and biological activity of some ring-substituted tryptamines, J. Med. Chem. 10:646–648.PubMedCrossRefGoogle Scholar
  131. Idänpään-Heikkilä, J. E., and McIsaac, W. M., 1970, 2,5-Dimethoxy-4-methylamphetamine tissue distribution and neurochemical action, Biochem. Pharmacol. 19:935–937.PubMedCrossRefGoogle Scholar
  132. Idänpään-Heikkilä, J. E., McIsaac, W. M., and Ho, B. T., 1969, Relation of pharmacological and behavioral effects of a hallucinogenic amphetamine to distribution in rat brain, Science 164:1085–1087.PubMedCrossRefGoogle Scholar
  133. Idänpään-Heikkilä, J. E., McIsaac, W. M., and Ho, B. T., 1969, Relation of pharmacological and behavioral effects of a hallucinogenic amphetamine to distribution in rat brain, Science 164:1085–1087.Google Scholar
  134. Isbell, H., Miner, E. J., and Logan, C. R., 1959, Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25), Psychopharmacologia 1:20–28.PubMedCrossRefGoogle Scholar
  135. Jacob, J., and Lafille, C., 1963, Pharmacological characterization and detection of hallucinogenic substances. Hyperthermic activity in rabbits, Arch. Int. Pharmacodyn. 145:528–545.PubMedGoogle Scholar
  136. Jacob, J., Loiseau, G., Echinard-Garin, P., and Barthelemy, C., 1962, Recherche d’equivalents expérimentaux au pouvoir hallucinogène, Med. Exp. 7:296–304.Google Scholar
  137. Jacob, P., III, Anderson, G., III, Meshul, C. K., Shulgin, A. T., and Castagnoli, N., Jr., 1977, The monomethylthio analogs of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane, J. Med. Chem. in press.Google Scholar
  138. Jansen, M. P. J. M., 1931, β-2,4,5-Trimethoxyphenylethylamine, an isomer of mescaline, Rec. Trav. Chim. 50:291–312.CrossRefGoogle Scholar
  139. Jolly, F., 1896, Ueber Pellotin als Schlafmittel, Deut. Med. Wochen. 22:375–376.CrossRefGoogle Scholar
  140. Kalbhen, D. A., and Braun, G., 1973, A new concept and further support for the importance and occurrence of 3,4-dimethoxyphenethylamine (DMPEA) in urine of schizophrenic patients, Pharmacology 9:52–56.PubMedCrossRefGoogle Scholar
  141. Kalbhen, D. A., Sargent, T., Shulgin, A. T., Braun, G., Stauffer, H., Kusubov, N., and Nohr, M. L., 1974, Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxy-phenylisopropylamine labelled with 82Br, I.R.C.S. 2:1091.Google Scholar
  142. Rang, S., and Green, J. P., 1970, Correlation between activity and electronic state of hallucinogenic amphetamines, Nature 226:645.CrossRefGoogle Scholar
  143. Kapatia, G. J., and Fayez, M. B. E., 1973, The chemistry of peyote alkaloids, Lloydia 36:9–35.Google Scholar
  144. Keaton, R., 1973, Additional information of 4-methylamphetamine, Microgram 6:98–100.Google Scholar
  145. Kelley, J. M., and Adamson, R. H., 1973, A comparison of common interatomic distances in serotonin and some hallucinogenic drugs, Pharmacology 10:28–31.PubMedCrossRefGoogle Scholar
  146. Klüver, H., 1928, Mescal, and Mechanisms of Hallucinations, Univ. of Chicago Press, Chicago. [Phoenix Science Series, 1966.]Google Scholar
  147. Knoll, E., and Wisser, H., 1976, Radioimmunologische Bestimmung von 3,4-Dimethoxyphenyläthylamine im Urin, Clin. Chim. Acta 68:327–332.PubMedCrossRefGoogle Scholar
  148. Knoll, J., Vizi, E. S., and Knoll, B., 1970, Pharmacological studies on para-bromomethamphetamine (V-111) and LSD, Acta Physiol. Acad. Sci. Hung. 37:151–170.PubMedGoogle Scholar
  149. Kulkarni, A. S., 1973, Scratching response induced in mice by mescaline and related amphetamine derivatives, Biol. Psychiat. 6:177–180.PubMedGoogle Scholar
  150. Kumbar, M., and Siva Sankar, D. V., 1973, Quantum chemical studies on drug actions. III. Correlation of hallucinogenic and anti-serotonin activity of lysergic acid derivatives with quantum chemical data, Res. Comm. Chem. Path. Pharm. 6:65–100.Google Scholar
  151. La Barre, W., 1969, The Peyote Cult, Schlocken, New York.Google Scholar
  152. Lehmann, H. E., 1958, Tranquillizers and other psychotropic drugs in clinical practice, Can. Med. Assoc. J. 79:701.PubMedGoogle Scholar
  153. Lehmann, H. E., 1959, Classification and terminology of psychotropic drugs, in Psychopharmacological Frontiers (N. J. Klein ed.), Churchill, London.Google Scholar
  154. Lewin, L., 1924, Phantasica, Narcotic and Stimulating Drugs, Engl. transl. 2nd ed., Rouledge and Kegan, 1964.Google Scholar
  155. Lipman, V. C., Shurrager, P. S., and Abood, L. G., 1963, Effect of anticholinergic psychotomimetics on motor activity and body temperature, Arch. Int. Pharmacodyn. 146:174–191.PubMedGoogle Scholar
  156. Loman, J., Myerson, P. G., and Myerson, A., 1941, Experimental pharmacology of post-encephalitic Parkinson’s disease, Trans. Am. Neurol. Assoc. 67:201–203.Google Scholar
  157. Luduena, F. P., 1935, Sobre la farmacologia de la tricocereina, alcaloide del Trichocereus terscheki (Parm.) Britton and Rose, Rev. Soc. Arg. Biol. 11:604–610.Google Scholar
  158. Luduena, F. P., 1936, Pharmacologie de la trichocereine, alkaloïde du Trichocereus terscheki (Parm.) Britton et Rose, CTS Biol. 121:368–369.Google Scholar
  159. Lundström, J., 1971a, Biosynthesis of mescaline and tetrahydroisoquinoline alkaloids in Lophophora williamsii (Lern.) Coult. Occurrence and biosynthesis of catecholamine and other intermediates, Acta Chem. Scand. 25:3489–3499.PubMedCrossRefGoogle Scholar
  160. Lundström, J., 1971b, Biosynthesis of tetrahydroisoquinoline alkaloids in Lophophora williamsii (Lern.) Coult., Acta Pharm. Suicida 8:485.Google Scholar
  161. Lundström, J., and Agurell, S., 1968, Gas chromatography of peyote alkaloids. A new peyote alkaloid, J. Chromatogr. 36:105–108.CrossRefGoogle Scholar
  162. McLaughlin, J. L., and Paul, A. G., 1965, Presence of hordenine in Lophophora williamsii, J. Pharm. Sci. 54:661.PubMedCrossRefGoogle Scholar
  163. McLaughlin, J. L., and Paul, A., 1966, Identification of N-methyltyramine derivatives in Lophophora williamsii, Lloydia 29:315–327.Google Scholar
  164. Mannich, C., and Jacobsohn, W., 1910, Über Oxyphenyl-alkylamine und Dioxyphenyl-Alkylamine, Chem. Ber. 43:189–197.CrossRefGoogle Scholar
  165. Marriott, A., and Rachlin, C. K., 1971, Peyote, Crowell, New York.Google Scholar
  166. Marsh, D. F., and Herring, D. A., 1950, The pharmacological activity of the ring methyl substituted phenylisopropylamines, J. Pharm. Exp. Ther. 100:298–308.Google Scholar
  167. Matin, S. B., Callery, P. S., Zweig, J. S., O’Brien, A., Rapaport, R., and Castagnoli, N., Jr., 1974, Stereochemical aspects and metabolic formation in the in vivo metabolism of the psychotomimetic amine 1-(2,5-dimethoxy-4-methyl)-2-aminopropane, J. Med. Chem. 17:877–882.PubMedCrossRefGoogle Scholar
  168. Menon, M. K., Tseng, L.-F., and Loh, H. H., 1976, Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines, J. Pharm. Exp. Ther. 197:272–279.Google Scholar
  169. Meyers, F. H., Rose, A. J., and Smith, D. E., 1968, Incidents involving the Haight-Ashbury population and some uncommonly used drugs, J. Psychedelic Drugs 1:139–146.CrossRefGoogle Scholar
  170. Michaux, R., and Verly, W. G., 1963, Action catalepsigene des ethers methylique des mono-et polyphenolamines, Life Sci. 3:175–183.PubMedCrossRefGoogle Scholar
  171. Midha, K. K., 1974, Identification of two in vivo metabolites of 3,4-methylenedioxyamphetamine by gas-liquid chromatography-mass spectrometry, J. Chromatogr. 101:210–214.PubMedCrossRefGoogle Scholar
  172. Mitoma, C., 1970, Metabolic studies on trimethoxyamphetamines, Proc. Soc. Exp. Biol. Med. 134:1162–1164.PubMedGoogle Scholar
  173. Monroe, R. R., and Drell, H. J., 1947, Oral use of stimulants obtained from inhalers, J. Am. Med. Soc. 135:909–915.Google Scholar
  174. Morin, R. D., Benington, F., Mitchell, S. R., Beaton, J. M., Bradley, R. J., and Smythies, J. R., 1975, The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines, Experientia 31:93–95.PubMedCrossRefGoogle Scholar
  175. Morishita, H., Nakano, S., Satoda, K., and Inoi, T., 1956, beta-(o-Alkoxy-phenyl)isopropylamines, Patent (Japan) 8021 (CA 52:11918e).Google Scholar
  176. Naranjo, C., 1967, Psychotropic Properties of the Harmala Alkaloids. Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), USGPO Public Health Service Publication #1645, pp. 385-391.Google Scholar
  177. Naranjo, C., 1973, The Healing Journey: New Approaches to Consciousness, Pantheon, New York.Google Scholar
  178. Naranjo, C., Shulgin, A. T., and Sargent, T., 1967, Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct of psychotherapy, Med. Pharmacol. Exp. 17:359–364.Google Scholar
  179. Neal, J. M., Sato, P. T., Howalt, W. N., and McLaughlin, J. L., 1972, Peyote alkaloids: Identification in the mexican cactus Pelecyphora aselliformis, Science 176:1131.PubMedCrossRefGoogle Scholar
  180. Nichols, D. E., and Shulgin, A. T., 1976, Sulfur analogs of psychotomimetic amines, J. Pharm. Sci. 65:1554–1556.PubMedCrossRefGoogle Scholar
  181. Nichols, D. E., Shulgin, A. T., and Dyers, D. C., 1977, Directional lipophilic character in in vitro serotonin activity in a series of psychotomimetic derivatives, Psychopharmacol. Commun., in press.Google Scholar
  182. Osmond, H., 1956, A review of the clinical effects of psychotomimetic agents, Ann. N.Y. Acad. Sci. 66:418–434.CrossRefGoogle Scholar
  183. Oswald, E. O., Fishbein, L., and Corbett, B. J., 1969, Metabolism of naturally occurring propenyl benzene derivatives. I. Chromatographic separation of ninhydrin-positive materials from rat urine, J. Chromatogr. 45:437–445.PubMedCrossRefGoogle Scholar
  184. Oswald, E. O., Fishbein, L., Corbett, B. J., and Walker, M. P., 1971a, Identification of tertiary amino-methylenedioxypropiophenones as urinary metabolites of safrole in the rat and guinea pig, Biochem. Biophys. Acta 230:237–247.PubMedCrossRefGoogle Scholar
  185. Oswald, E. O., Fishbein, L., Corbett, B. J., and Walker, M. P., 1971nb, Urinary excretion of tertiary aminomethoxymethylenedioxypropiophenones as metabolites of myristicin in the rat and guinea pig, Biochem. Biophys. Acta 244:322–328.PubMedCrossRefGoogle Scholar
  186. Pahnke, W. N., and Richards, W. A., 1966, Implications of LSD and experimental mysticism, J. Rel. Health 5:175.CrossRefGoogle Scholar
  187. Parli, C. J., and Schmidt, B., 1975, Metabolism of 4-chloroamphetamine to 3-chloro-4-hydroxyamphetamine in rat: Evidence for an in vivo “NIH shift” of chlorine, Res. Commun. Chem. Path. Pharmacol. 10:601–604.Google Scholar
  188. Paul, A., 1973, Biosynthesis of the peyote alkaloids, Lloydia 36:36–45.PubMedGoogle Scholar
  189. Peretz, D. I., Smythies, J. R., and Gibson, W. C., 1955, A new hallucinogen: 3,4,5-trimethoxyphenyl-beta-aminopropane (with notes on a stroboscopic phenomenon), J. Mental. Sci. 101:317–329.Google Scholar
  190. Perry, T. L., Hansen, S., and Macintyre, L., 1964, Failure to detect 3,4-dimethoxyphenylethylamine in the urine of schizophrenics, Nature 202:519–520.PubMedCrossRefGoogle Scholar
  191. Pletscher, A., Burkard, W. P., Bruderer, H., and Gey, K. F., 1963, Decrease in cerebral 5-HT and 5-hydroxyindoleacetic acid by an aryl alkyl amine, Life Sci. 2:828–833.CrossRefGoogle Scholar
  192. Poisson, M. J., 1960, Présence de mescaline dans une cactacée péruvienne, Ann. Pharm. Franc. 18:764–765.PubMedGoogle Scholar
  193. Prinzmetal, M., and Bloomberg, W., 1935, The use of benzedrine for the treatment of narcolepsy, J. Am. Med. Assoc. 105:2051–2054.CrossRefGoogle Scholar
  194. Reti, L., 1939, Nuovi alcaloidi di cactacee argentine, Atti X Congr. Int. Chim., Roma 5:396–405.Google Scholar
  195. Reti, L., and Castrillón, J. A., 1951, Cactus alkaloids. I. Trichocereus terscheckii (Parmentier) Britton and Rose, J. Am. Chem. Soc. 73:1767–1769.CrossRefGoogle Scholar
  196. Riceberg, L. J., and Vunakis, H. V., 1975, Estimation of β-3,4-dimethoxyphenethylamine and related compounds in urine extracts by radioimmunoassay, Biochem. Pharm. 24:259–265.PubMedCrossRefGoogle Scholar
  197. Rouhier, A., 1926, Monographie du Peyotl Echinocactus williamsii Lem, Lucien Decluma, Lonsle-Saunier.Google Scholar
  198. Sanders-Bush, E., Bushing, J. A., and Sulser, F., 1972, Long-term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain, Eur. J. Pharmacol. 20:385–388.PubMedCrossRefGoogle Scholar
  199. Sargent, T., Kalbhen, D. A., Shulgin, A. T., Stauffer, H., and Kusubov, N., 1975a, A potential new brain-scanning agent, 4-77Br-2,5-dimethoxyphenylisopropylamine (4-Br-DPIA), J. Neuc. Med. 16:243–245.Google Scholar
  200. Sargent, T., Kalbhen, D. A., Shulgin, A. T., Braun, G., Stauffer, H., and Kusubov, N., 1975b, In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxy-phenylisopropylamine labelled with 82Br or 77Br, Neuropharmacology 14:165–174.PubMedCrossRefGoogle Scholar
  201. Sargent, T., Shulgin, A. T., and Kusubov, N., 1976, Quantitative measurement of demethylation of 14C-methoxy labeled DMPEA and TMA-2 in rats, Psychopharmacol. Commun. 2:199–206.PubMedGoogle Scholar
  202. Sargent, T., III, Budinger, T. F., Shulgin, A. T., Braun, G., and Braun, U., 1977, Brain uptake of a radioiodine labeled psychotomimetic in dog and monkey, J. Biol. Psychiat. (submitted; presented at Soc. Biol. Psychiat. Meeting, Toronto, April, 1977).Google Scholar
  203. Schneider, C. W., and Chenoweth, M. B., 1970, Effects of hallucinogenic and other drugs on the nest-building behavior of mice, Nature 225:1262–1263.PubMedCrossRefGoogle Scholar
  204. Schultes, R. E., 1972, An overview of hallucinogens in the Western Hemisphere, see Furst (1972), pp. 3-54.Google Scholar
  205. Schultes, R. E., and Hofmann, A., 1973, The Botany and Chemistry of Hallucinogens, Charles C. Thomas, Springfield, Illinois.Google Scholar
  206. Schweitzer, J. W., and Friedhoff, A. J., 1968, The metabolism of dimethoxyphenethylamine, a compound found in the urine of schizophrenics, Am. J. Psychiat. 124:1249–1253.PubMedGoogle Scholar
  207. Schweitzer, J. W., and Friedhoff, A. J. 1970, Amphetamines in human urine: Rapid estimation by gas-liquid chromatography, Clin. Chem. 16:786–788.PubMedGoogle Scholar
  208. Schweitzer, J. W., Friedhoff, A. J., Angrist, B. M., and Gershon, S., 1971, Excretion of p-methoxyamphetamine administered to humans, Nature 229:133–134.PubMedCrossRefGoogle Scholar
  209. Seiler, N., and Demisch, L., 1971, Oxidative metabolism of mescaline in the central nervous system. II. Oxidative deamination of mescaline and 2,3,4-trimethoxy-beta-phenethylamine by different mouse brain areas in vitro, Biochem. Pharm. 20:2485–2493.PubMedCrossRefGoogle Scholar
  210. Sen, N. P., and McGeer, P. L., 1964, 4-Methoxyphenylethylamine and 3,4-dimethoxyphenylethylamine in human urine, Biochem. Biophys. Res. Commun. 14:227–232.PubMedCrossRefGoogle Scholar
  211. Sepulveda, S., Valenzuela, R., and Cassels, B. K., 1972, Potential psychotomimetics. New bromoalkoxyamphetamines. J. Med. Chem. 15:413–415.PubMedCrossRefGoogle Scholar
  212. Severs, P. S., Dring, L. G., and Williams, R. T., 1976, Urinary metabolites of p-hydroxyamphetamine in man, rat, and guinea pig, Xenobiotica 6:345–353.CrossRefGoogle Scholar
  213. Shaler, R. C., and Padden, J. J., 1972, Identification of hallucinogens in illicit seizures. I. 2,5-Dimethoxyamphetamine, J. Pharm. Sci. 61:1851–1855.CrossRefGoogle Scholar
  214. Sherman, A. D., and Gál, E. M., 1976, Mass-spectrographic evidence of the conversion of p-chloroamphetamine to 3,4-dimethoxyamphetamine, Psychopharm. Commun. 2:421–427.Google Scholar
  215. Shulgin, A. T., 1964a, Psychotomimetic amphetamines: Methoxy 3,4-dialkoxyamphetamines, Experientia 20:366–367.PubMedCrossRefGoogle Scholar
  216. Shulgin, A. T., 1964b, 3-Methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent, Nature 201:1120–1121.PubMedCrossRefGoogle Scholar
  217. Shulgin, A. T., 1966a, The six trimethoxyphenylisopropylamines (trimethoxyamphetamines), J. Med. Chem. 9:445–446.PubMedCrossRefGoogle Scholar
  218. Shulgin, A. T., 1966b, Possible implication of myristicin as a pyschotropic substance, Nature 210:380–384.PubMedCrossRefGoogle Scholar
  219. Shulgin, A. T., 1968, The ethyl homologs of 2,4,5-trimethoxyphenylisopropylamine, J. Med. Chem. 11:186–187.PubMedCrossRefGoogle Scholar
  220. Shulgin, A. T., 1970a, Chemistry and structure-activity relationships of the psychotomimetics, in Psychotomimetic Drugs (D. H. Efron, ed.), Raven Press, New York.Google Scholar
  221. Shulgin, A. T., 1970b, 4-Alkyl-alpha-methyl phenethylamines and their pharmacologically acceptable salts, U.S. Patent 3,547,999.Google Scholar
  222. Shulgin, A. T., 1971, Preliminary studies of the synthesis of nitrogen analogs of delta-1THC, Acta Pharm. Suecica 8:680–681.Google Scholar
  223. Shulgin, A. T., 1973a, Mescaline: The chemistry and pharmacology of its analogs, Lloydia 36:46–58.PubMedGoogle Scholar
  224. Shulgin, A. T., 1973b, Stereospecific requirements for hallucinogenisis, J. Pharm. Pharmacol. 25:271–272.PubMedCrossRefGoogle Scholar
  225. Shulgin, A. T., 1976a, Psychotomimetic agents in Psychopharmacological Agents, Vol. 4 (M. Gordon, ed.), Academic Press, New York.Google Scholar
  226. Shulgin, A. T., 1976b, Abuse of the term “amphetamines,” Clin. Toxicol. 9:351–352.PubMedCrossRefGoogle Scholar
  227. Shulgin, A. T., 1976c, Profiles of psychedelic drugs. 2. TMA-2, J. Psychedelic Drugs 8:169.Google Scholar
  228. Shulgin, A. T., and Carter, M. F., 1975, Centrally active phenethylamines, Psychopharmacol. Commun. 1:93–98.PubMedGoogle Scholar
  229. Shulgin, A. T., and Dyer, D. C., 1975, Psychotomimetic phenylisopropylamines. V. 4-Alkyl-2,5-dimethoxyphenylisopropylamines, J. Med. Chem. 18:1201–1204.PubMedCrossRefGoogle Scholar
  230. Shulgin, A. T., and Nichols, D. E., 1977, Characterization of three new psychotomimetics, in Psychopharmacology of Hallucinogens (R. Stillman, ed.), Pergamon Press, New York.Google Scholar
  231. Shulgin, A. T., and Sargent, T., 1967, Psychotropic phenylisopropylamines derived from apiole and dillapiole, Nature 215:1494–1495.PubMedCrossRefGoogle Scholar
  232. Shulgin, A. T., Bunnell, S., and Sargent, T., 1961, The psychotomimetic properties of 3,4,5-trimethoxyamphetamine, Nature 189:1011–1012.CrossRefGoogle Scholar
  233. Shulgin, A. T., Sargent, T., and Naranjo, C., 1966, Role of 3,4-dimethoxyphenethylamine in schizophrenia, Nature 212:1606–1607.PubMedCrossRefGoogle Scholar
  234. Shulgin, A. T., Sargent, T., and Naranjo, C., 1967, The chemistry and psychopharmacology of nutmeg and several related phenylisopropylamines, in The Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), pp. 202-214, USGPO.Google Scholar
  235. Shulgin, A. T., Sargent, T., and Naranjo, C., 1969, Structure-activity relationships of one-ring psychotomimetics, Nature 221:537–541.PubMedCrossRefGoogle Scholar
  236. Shulgin, A. T., Sargent, T., and Naranjo, C., 1971, 4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog, Pharmacology 5:103–107.PubMedCrossRefGoogle Scholar
  237. Shulgin, A. T., Sargent, T., and Naranjo, C., 1973, Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenyliospropylamine (MMDA), Pharmacology 10:12–18.PubMedCrossRefGoogle Scholar
  238. Silva, M. T. A., and Calil, H. M., 1975, Screening hallucinogenic drugs. Systematic study of three behavioral tests, Psychopharmacologia 42:163–171.PubMedCrossRefGoogle Scholar
  239. Slotkin, J. S., 1956, The Peyote Religion, The Free Press, Glencoe, Illinois.Google Scholar
  240. Slotta, K. H., and Heller, H., 1930, Über beta-Phenethylamine. I. Mezcalin-ahnlicher Substanzen, Chem. Ber. 63:3029–3044.Google Scholar
  241. Slotta, K. H., and Müller, J., 1936, Über den Abbau des Mescalins und mescalinähnlicher Stoffe im Organismus, Z. Physiol. Chem. 238:14–22.CrossRefGoogle Scholar
  242. Smith, D. E., 1969, The psychotomimetic amphetamines with special reference to DOM (STP) toxicity, J. Psychedelic Drugs 2:37–41.CrossRefGoogle Scholar
  243. Smythies, J. R., and Levy, C. K., 1960, The comparative psychopharmacology of some mescaline analogs, J. Mental Sci. 106:531–536.Google Scholar
  244. Smythies, J. R., Bradley, R. J., Johnson, V. S., Benington, F., Morin, R. D., and Clark, L., 1967a, Structure-activity relationship on of mescaline. III. The influence of the methoxy groups, Psychopharmacologia 10:379–387.PubMedCrossRefGoogle Scholar
  245. Smythies, J. R., Johnson, V. S., and Bradley, R. J., 1967b, Alteration by pretreatment with iproniazid and an inactive mescaline analogue of the behavioral change by mescaline, Nature 216:196–197.PubMedCrossRefGoogle Scholar
  246. Smythies, J. R., Johnson, V. S., Bradley, R. J., Benington, F., Morin, R. D., and Clark, L. C., 1967c, Some new behavior-disrupting amphetamines and their significance, Nature 216:128–129.PubMedCrossRefGoogle Scholar
  247. Smythies, J. R., Johnson, V. S., and Bradley, R. J., 1969, Behavioral models of psychosis, Br. J. Psychiat. 115:55–68.CrossRefGoogle Scholar
  248. Smythies, J. R., Benington, F., and Morin, R., 1970, The mechanism of action of hallucinogenic drugs on a possible serotonin receptor in the brain, Int. Rev. Neurobiol. 12:207–236.PubMedCrossRefGoogle Scholar
  249. Snyder, S. H., and Merril, C. R., 1965, A relationship between the hallucinogenic activity of drugs and their electronic configuration, Proc. Nat. Acad. Sci. 54:258–266.PubMedCrossRefGoogle Scholar
  250. Snyder, S. H., and Richelson, E., 1968, Psychedelic drugs: Steric factors that predict psychotropic activity, Proc. Nat. Acad. Sci. 60:206–213.PubMedCrossRefGoogle Scholar
  251. Snyder, S. H., Faillace, L. A., and Hollister, L. E., 1967, 2,5-Dimethoxy-4-methylamphetamine (STP): A new hallucinogenic drug, Science 158:669–670.PubMedCrossRefGoogle Scholar
  252. Snyder, S. H., Faillace, L. A., and Weingartner, H., 1968, DOM (STP), A new hallucinogenic drug, and DOET: Effects in normal subjects, Am. J. Psychiat. 125:357–364.Google Scholar
  253. Snyder, S. H., Faillace, L. A., and Weingartner, H., 1969, A new psychotropic agent. Psychological and physiological effects of 2,5-dimethoxy-4-ethyl amphetamine (DOET) in man, Arch. Gen. Psychiat. 21:95–101.PubMedCrossRefGoogle Scholar
  254. Snyder, S. H., Weingartner, H., and Faillace, L. A., 1971, DOET (2,5-dimethoxy-4-ethylamphetamine), a new psychotropic drug. Effects of varying doses in man, Arch. Gen. Psychiat. 24:50–55.PubMedCrossRefGoogle Scholar
  255. Snyder, S. H., Unger, S., Blatchley, R., and Barfknecht, C. F., 1974, Stereospecific actions of DOET (2,5-dimethoxy-4-ethylamphetamine) in man, Arch. Gen. Psychiat. 31:103–106.PubMedCrossRefGoogle Scholar
  256. Späth, E., and Bruck, J., 1937, Über ein neues Alkaloid aus den Mezcal Buttons, Chem. Ber. 70:2446–2450.Google Scholar
  257. Späth, E., and Bruck, J., 1938, N-Acetylmezcalin als Inhaltsstoff der Mezcal Buttons, Chem. Ber. 71:1275–1276.Google Scholar
  258. Stone, C. A., 1963, Composition hypotensive et son utilisation, Brev. Belge, #633,963.Google Scholar
  259. Sugasawa, S., and Hino, T., 1954, Synthesis of 1-(3,4-methylenedioxyphenyl)-3,5-dimethyl-7,8-methylenedioxyisoquinoline, Pharm. Bull. (Japan) 2:242–246.Google Scholar
  260. Sung, M-T., and Parker, J. A., 1972, Amphetamines: Correlation of activity with stability of molecular complexes, Proc. Nat. Acad. Sci. 69:1346–1347.PubMedCrossRefGoogle Scholar
  261. Sung, M-T., and Parker, J. A., 1974, Molecular complexes between methoxyamphetamines and riboflavin derivatives, Z. Naturforsch. 29:122–127.Google Scholar
  262. Tacker, M., Creaven, P. J., and McIsaac, W. M., 1969, Preliminary observations on the metabolism of 3H-2,5-dimethoxy-4-methylamphetamine (STP, DOM) in Drug Dependence (R. T. Harris, W. M. McIsaac, and C. R. Schuster, eds.), pp. 21–23, Univ. of Texas Press, Austin, Texas.Google Scholar
  263. Tansey, L. W., Estevez, V. S., and Ho, B. T., 1975, Metabolic studies of 2,5-dimethoxy-4-ethylamphetamine (DOET) in rats, Proc. West. Pharmacol. Soc. 18:362.PubMedGoogle Scholar
  264. Todd, J. S., 1969, Thin layer chromatography analysis of Mexican populations of Lophophora (cactaceae), Lloydia 32:395–398.PubMedGoogle Scholar
  265. Tozman, S., Schweitzer, J. W., and Friedhoff, A. J., 1972, Demethylation of (4-methoxy-14C)-N-acetyl-3,4-dimethoxyphenethylamine in schizophrenics—A preliminary study, Life Sci. 11:1069–1078.CrossRefGoogle Scholar
  266. Tseng, L.-F., Menon, M. K., and Loh, H. H., 1976, Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue, J. Pharm. Exp. Ther. 197:263–271.Google Scholar
  267. Turek, I. S., Soskin, R. A., and Kurland, A. A., 1974, Methylenedioxyamphetamine (MDA) subjective effects, J. Psychedelic Drugs 6:7–14.CrossRefGoogle Scholar
  268. Turner, W. J., and Heyman, J. J., 1960, The presence of mescaline in Opuntia cylindrica, J. Org. Chem. 25:2250–2251.CrossRefGoogle Scholar
  269. Uyeno, E. T., 1968, Hallucinogenic compounds and swimming response, J. Pharm. Exp. Ther. 159:216–221.Google Scholar
  270. Uyeno, E. T., Otis, L. S., and Mitoma, C., 1968, Behavioral evaluation of hallucinogenic trimethoxyamphetamines in squirrel monkeys (Saimiri sciureus), Commun. Behav. Biol. 1:83–90.Google Scholar
  271. van Praag, H. M., and Korf, J., 1976, 4-Chloroamphetamines. Chance and trend in the development of new antidepressants, Psychopharmacol. Bull. 12(3):64–74.PubMedGoogle Scholar
  272. van Praag, H. M., Schut, T., Bosman, E., and van den Bergh, R., 1971, A comparative study of the therapeutic effects of some 4-chlorinated amphetamine derivatives in depressed patients, Psychopharmacologia 20:66–76.PubMedCrossRefGoogle Scholar
  273. Verster, J., and van Praag, H. M., 1970, A comparative investigation of methylamphetamine and 4-chloro-N-methylamphetamine in healthy test subjects, Pharmako-psychiatry 3:239–248.Google Scholar
  274. Vojtechovsky, M., and Krus, D., 1967, Psychotropic effect of mescaline-like drugs, Acta New. Sup., 381-383.Google Scholar
  275. von Studnitz, W., and Nyman, G. E., 1965, Excretion of 3,4-dimethoxyphenethylamine in schizophrenia, Acta Psychiat. Scand. 41:117–121.CrossRefGoogle Scholar
  276. Weil, A. T., 1967, Nutmeg as a psychoactive drug, in The Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), pp. 188-201, USGPO.Google Scholar
  277. Weingartner, H., Snyder, S. H., Faillace, L. A., and Markley, H., 1970, Altered free associations: Some cognitive effects of DOET (2,5-dimethoxy-4-ethylamphetamine), Behav. Sci. 15:297–303.CrossRefGoogle Scholar
  278. Weingartner, H., Snyder, S. H., and Faillace, L. A., 1971, DOM (STP). A new hallucinogenic drug: Specific perceptual changes, J. Clin. Pharmacol. 11:103–111.CrossRefGoogle Scholar
  279. Weinkam, R. J., Gal, J., Callery, P., and Castagnoli, N., Jr., 1976, Application of chemical ionization mass spectrometry to the study of stereoselective in vitro metabolism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane, Anal. Chem. 48:203–209.PubMedCrossRefGoogle Scholar
  280. Wenner, W., 1951, Hydroxyphenylisopropylamines containing nuclear methyl groups, J. Org. Chem. 16:457–460.CrossRefGoogle Scholar
  281. Winter, J. C., 1973, A comparison of the stimulus properties of mescaline and 2,3,4-trimethoxyphenylethylamine, J. Pharm. Pharmacol. 185:101–107.Google Scholar
  282. Yensen, R., DiLeo, F. B., Rhead, J. C., Richards, W. A., Soskin, R. A., Turek, B., and Kurland, A. A., 1976, MDA-assisted psychotherapy with neurotic outpatients: A pilot study, J. Nerv. Mental Dis. 163:233–245.CrossRefGoogle Scholar
  283. Yunger, L. M., McMaster, S. E., and Harvey, J. A., 1974, Neurotoxic effects of p-chloroamphetamine and 5-hydroxyindoleacetic acid in brain, Pharmacologist 16:244.Google Scholar
  284. Zweig, J. S., and Castagnoli, N., Jr., 1974, Chemical conversion of the psychotomimetic amine 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane to 5-hydroxy-2,6-dimethylindole, J. Med. Chem. 17:747–749.PubMedCrossRefGoogle Scholar
  285. Zweig, J. S., and Castagnoli, N., Jr., 1975, Metabolic O-demethylation of the psychotomimetic amine 1-(2,5-dimethoxy-4-methylphenyl)2-aminopropane, Psychopharmacol. Comm. 1:359–371.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Alexander T. Shulgin
    • 1
  1. 1.LafayetteUSA

Personalised recommendations